Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI

PURPOSE: Platinum-based chemotherapy remains the classic treatment option for patients with advanced non-small-cell lung cancer (NSCLC) who progress while receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). In this study, we analyzed real-world outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Haiyi, Lin, Xinqing, Xie, Xiaohong, Yang, Yilin, Wang, Liqiang, Wu, Jianhui, Liu, Ming, Xie, Zhanhong, Qin, Yinyin, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488293/
https://www.ncbi.nlm.nih.gov/pubmed/34616674
http://dx.doi.org/10.3389/fonc.2021.700023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488293/
https://www.ncbi.nlm.nih.gov/pubmed/34616674
http://dx.doi.org/10.3389/fonc.2021.700023

Ejemplares similares